China Universal Asset Management Co. Ltd. Increases Stock Position in Genmab A/S (NASDAQ:GMAB)

China Universal Asset Management Co. Ltd. increased its stake in shares of Genmab A/S (NASDAQ:GMAB) by 63.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,064 shares of the company’s stock after purchasing an additional 3,137 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Genmab A/S were worth $197,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. raised its stake in Genmab A/S by 137.7% during the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock valued at $28,000 after buying an additional 544 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Genmab A/S in the first quarter worth $43,000. Blue Trust Inc. grew its holdings in shares of Genmab A/S by 892.0% in the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after acquiring an additional 3,880 shares during the period. Headlands Technologies LLC increased its position in Genmab A/S by 1,702.8% during the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after acquiring an additional 4,853 shares during the last quarter. Finally, Thompson Davis & CO. Inc. bought a new position in Genmab A/S in the first quarter valued at about $202,000. Institutional investors own 7.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on GMAB. Morgan Stanley reaffirmed an “equal weight” rating and set a $31.00 price target on shares of Genmab A/S in a research report on Wednesday, September 11th. Royal Bank of Canada raised shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a report on Monday, July 15th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Wednesday, October 16th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Finally, Redburn Atlantic began coverage on Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Price Performance

Shares of GMAB stock opened at $22.57 on Thursday. Genmab A/S has a one year low of $22.39 and a one year high of $32.89. The company’s fifty day moving average price is $25.07 and its 200-day moving average price is $26.69. The company has a market capitalization of $14.94 billion, a price-to-earnings ratio of 18.65, a PEG ratio of 0.68 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The business had revenue of $779.50 million during the quarter, compared to analysts’ expectations of $734.60 million. Equities research analysts expect that Genmab A/S will post 1.29 earnings per share for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.